Related Experiment Video
Updated: Jul 12, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'
1Division of Urology, Duke University Medical Center, Durham, NC 27705, USA. Daniel.george@duke.edu
Abstract:
Although single-target agents have been shown to improve patient outcomes in certain tumour types, drug resistance often occurs due to salvage pathways that compensate for the inhibited signalling pathway. Simultaneous inhibition of individual target receptors along multiple pathways has been shown to have additive inhibitory effects on tumour growth and vasculature, and data supporting the efficacy of strategies incorporating multitargeted agents in the treatment of several tumour types have already begun to emerge in the clinical setting. This supplement provides an overview of presentations from a satellite symposium that took place at the European Society of Medical Oncology congress on 29 September 2006, entitled 'A Multitargeted Approach: Clinical Advances in the Treatment of Solid Tumours', which discusses the most recent data on multitargeted agents with a focus on sunitinib malate (Sutent, Pfizer Inc.).
Insights
Multitargeted cancer therapies overcome drug resistance by inhibiting multiple pathways simultaneously. This approach shows promise in treating solid tumours, with sunitinib malate as a key example.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Single-target cancer agents face challenges due to drug resistance mediated by compensatory salvage pathways.
- Multitargeted agents offer a strategy to overcome resistance by simultaneously inhibiting multiple signalling pathways.
Discussion:
- The symposium focused on clinical advances in treating solid tumours using multitargeted agents.
- Presentations highlighted recent data on the efficacy of these agents in various cancer types.
- Sunitinib malate (Sutent) was a key focus, showcasing its role in multitargeted therapy.
Key Insights:
- Simultaneous inhibition of multiple targets can enhance anti-tumour effects and inhibit tumour vasculature.
- Emerging clinical data support the effectiveness of multitargeted strategies in solid tumour treatment.
- Multitargeted agents represent a significant advancement over single-target therapies in managing cancer drug resistance.
Outlook:
- Further clinical investigation and application of multitargeted agents are anticipated.
- Sunitinib malate and similar agents are expected to play a growing role in personalized cancer treatment.
- The development of novel multitargeted therapies holds promise for improving patient outcomes in oncology.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
